Neuroone Med Technologies Corp Stock Price, News & Analysis

NeuroOne Medical Technologies (Nasdaq: NMTC) has received a notice of allowance from the USPTO for a key patent titled "Methods for Making Probe Devices and Related Devices." The patent application (17/392,773) covers novel methods for manufacturing neural probe devices, including specific processes for probe component arrangement and electrode contact material deposition.

The company's intellectual property portfolio now encompasses 17 issued and pending patents across the U.S. and internationally, covering various thin-film electrode technologies. The patent is expected to be formally issued in the coming months, strengthening NeuroOne's position in neural and spinal cord electrode technology.

NeuroOne Medical Technologies Corporation announced a significant milestone as Clara, one of their early patients treated with the OneRF® Ablation System, has remained seizure-free for over a year. Prior to treatment in June 2024, Clara experienced up to 10 seizures daily. The OneRF® Ablation System, which is FDA 510(k)-cleared, is unique as the first device allowing both diagnostic and therapeutic applications using the same sEEG electrode, with bedside ablation capability. The technology has shown promising results in seizure reduction or elimination for most treated patients. NeuroOne is now expanding the technology's applications, having filed a 510(k) submission for a Trigeminal Nerve Ablation System to treat facial pain in April 2025. Clara's successful treatment has enabled her to pursue college full-time and enjoy daily activities previously impacted by seizures.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has appointed Emily Johns as General Counsel and Corporate Secretary. Johns, previously a partner at Honigman LLP, brings extensive experience in securities and corporate governance, having represented NeuroOne since 2017. CEO Dave Rosa highlighted that Johns' appointment would strengthen the management team while reducing legal costs. As part of her compensation, Johns received options to purchase 500,000 shares at $0.611 per share. Additionally, the company granted its new senior director of quality assurance and regulatory affairs options for 75,000 shares under the same terms, with 25% vesting after one year and the remainder in quarterly installments.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), a medical technology company specializing in neurological disorder surgical care solutions, has announced its participation in the upcoming MedInvest MedTech, AI and Digital Health Conference. The event will take place on June 3-4, 2025, at the O'Melveny Conference Center in San Francisco, CA.

Dave Rosa, President and CEO of NeuroOne, will be conducting investor meetings during this two-day conference, which will feature panel discussions, keynote talks, and corporate presentations focusing on medical devices, imaging technologies, diagnostics, AI/data analytics, and digital health. The MedInvest Conference is recognized as a leading conference series in Healthcare and Life Sciences, hosting semiannual events in Biotech, Pharma, MedTech, AI, and Digital Health sectors.

NeuroOne Medical Technologies (NASDAQ: NMTC) reported strong Q2 FY2025 financial results, with significant gross margin improvement to 55.6% from 28.3% YoY. Product revenue remained stable at $1.4M for Q2, while H1 FY2025 product revenue grew 98% to $4.7M. The company successfully filed an FDA submission for its OneRF® Trigeminal Nerve Ablation System ahead of schedule and completed an oversubscribed $8.2M capital raise in April 2025.

The company reaffirmed its FY2025 product revenue guidance of $8.0-10.0M, representing 132-190% growth YoY. NeuroOne strengthened its management team with key appointments and remains debt-free, with funding secured through FY2026. The first patient treated with OneRF Ablation System will reach one year of seizure freedom in June 2025, marking a significant milestone for the company's technology.

NeuroOne Medical Technologies (NASDAQ: NMTC) has appointed Dr. Parag G. Patil as Chief Medical Advisor (CMA), upgrading his role from the company's Scientific Advisory Board where he has served since 2018. Dr. Patil, a neurosurgeon-engineer with 20 years of experience, is currently an Associate Professor at the University of Michigan in multiple departments and serves as Associate Chair for Clinical and Translational Research.

Dr. Patil's expertise spans electrophysiology, imaging, and mathematical modeling, with a focus on developing improved therapies for paralysis, pain, and movement disorders using neural-interface devices. In his new role, he will assist with NeuroOne's clinical strategy, product development, physician education, and professional society partnerships while maintaining his faculty position.

NeuroOne Medical (NASDAQ: NMTC) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. The company's CFO, Ron McClurg, will be available for one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), a medical technology company specializing in neurological disorder treatments, will announce its fiscal second quarter 2025 financial results on May 13, 2025, before market open. The company will host an investor conference call and webcast at 8:30 a.m. Eastern time the same day.

Management will discuss Q2 financial results, provide corporate updates, and hold a Q&A session. The conference call can be accessed via U.S. toll-free number (888-506-0062) or international number (973-528-0011) using participant code 655933. A playback will be available until May 27, 2025, through domestic (877-481-4010) and international (919-882-2331) numbers with replay passcode 52404.

NeuroOne Medical Technologies (Nasdaq: NMTC) has submitted a 510(k) application to the FDA for its OneRF® Trigeminal Nerve Ablation System, ahead of schedule. The system aims to treat trigeminal neuralgia, a chronic facial pain condition affecting approximately 100,000 Americans.

The technology features a minimally invasive surgical procedure using radiofrequency energy to destroy abnormal tissue. Key features include multi-point mapping of pain location, stimulation, and temperature-controlled ablation, all using the same electrode. Published data indicates RF ablation achieves ~95% initial pain relief rates with long-term efficacy and low complication rates.

If FDA cleared, NeuroOne anticipates potential revenue generation from trigeminal nerve ablation by late 2025. The system builds upon the company's FDA-cleared OneRF sEEG Ablation System for brain procedures.